The effect of the controlled release of basic fibroblast growth factor from ionic gelatin-based hydrogels on angiogenesis in a murine critical limb ischemic model.

[1]  M. Dashwood,et al.  The Effect of Acute Ischemia on ET-1 and Its Receptors in Patients with Underlying Chronic Ischemia of the Lower Limb , 2006, Experimental biology and medicine.

[2]  M. Poon,et al.  G‐CSF‐mobilized peripheral blood mononuclear cells from diabetic patients augment neovascularization in ischemic limbs but with impaired capability , 2006, Journal of thrombosis and haemostasis : JTH.

[3]  S. Pham,et al.  Therapeutic angiogenesis in critical limb ischemia via the localized delivery of bFGF from ionic hydrogels , 2006 .

[4]  A. Avogaro,et al.  Autologous transplantation of granulocyte colony-stimulating factor- mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. , 2006, Diabetes care.

[5]  A. Giatromanolaki,et al.  Angiogenic effect of intramuscular administration of basic and acidic fibroblast growth factor on skeletal muscles and influence of exercise on muscle angiogenesis , 2005, British Journal of Sports Medicine.

[6]  Antonios G Mikos,et al.  Gelatin as a delivery vehicle for the controlled release of bioactive molecules. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Ngan F Huang,et al.  Injectable biopolymers enhance angiogenesis after myocardial infarction. , 2005, Tissue engineering.

[8]  Z. Han,et al.  Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. , 2005, Diabetes care.

[9]  S. Goodman,et al.  Management of risk in peripheral artery disease: recent therapeutic advances. , 2005, American heart journal.

[10]  M. Gümüşderelioğlu,et al.  Controlled release of EGF and bFGF from dextran hydrogels in vitro and in vivo. , 2005, Journal of biomedical materials research. Part B, Applied biomaterials.

[11]  R. Graham,et al.  Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle , 2005, Gene Therapy.

[12]  W. Aronow.  Management of Peripheral Arterial Disease , 2005, Cardiology in review.

[13]  E. Kardami,et al.  Beyond angiogenesis: the cardioprotective potential of fibroblast growth factor-2. , 2004, Canadian journal of physiology and pharmacology.

[14]  C. Doillon,et al.  Denatured collagen as support for a FGF-2 delivery system: physicochemical characterizations and in vitro release kinetics and bioactivity. , 2004, Biomaterials.

[15]  Won Ho Park,et al.  Electrospinning of silk fibroin nanofibers and its effect on the adhesion and spreading of normal human keratinocytes and fibroblasts in vitro. , 2004, Biomaterials.

[16]  A. Siegbahn,et al.  Activation of coagulation and fibrinolytic systems in patients with CLI is not normalized after surgical revascularisation. , 2004, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[17]  Matthias P Lutolf,et al.  Biopolymeric delivery matrices for angiogenic growth factors. , 2003, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[18]  Y. Tabata,et al.  Gelatin sheet incorporating basic fibroblast growth factor enhances sternal healing after harvesting bilateral internal thoracic arteries. , 2003, The Journal of thoracic and cardiovascular surgery.

[19]  K. Gilmartin,et al.  Alginate for endovascular treatment of aneurysms and local growth factor delivery. , 2003, AJNR. American journal of neuroradiology.

[20]  K. Shyu,et al.  Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. , 2003, The American journal of medicine.

[21]  J. Veerkamp,et al.  Loading of collagen-heparan sulfate matrices with bFGF promotes angiogenesis and tissue generation in rats. , 2002, Journal of biomedical materials research.

[22]  R. Lederman,et al.  Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial☆ , 2002 .

[23]  R. Lederman,et al.  Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial , 2002, The Lancet.

[24]  H. Rasmussen,et al.  VEGF gene therapy for coronary artery disease and peripheral vascular disease. , 2002, Cardiovascular radiation medicine.

[25]  D. Mooney,et al.  Polymeric system for dual growth factor delivery , 2001, Nature Biotechnology.

[26]  A. Comerota.  Endovascular and surgical revascularization for patients with intermittent claudication. , 2001, The American journal of cardiology.

[27]  F. Sellke,et al.  Therapeutic angiogenesis in cardiology using protein formulations. , 2001, Cardiovascular research.

[28]  A. Quyyumi,et al.  Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. , 2000, Journal of the American College of Cardiology.

[29]  M. Humphries,et al.  Molecular Basis of Ligand Recognition by Integrin α5β1 , 2000, The Journal of Biological Chemistry.

[30]  M. Nugent,et al.  Fibroblast growth factor-2. , 2000, The international journal of biochemistry & cell biology.

[31]  Y. Ikada,et al.  Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities. , 1999, Biomaterials.

[32]  J. Isner,et al.  Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. , 1999, The American journal of pathology.

[33]  Ikada,et al.  Protein release from gelatin matrices. , 1998, Advanced drug delivery reviews.

[34]  Y. Ikada,et al.  Bone regeneration by basic fibroblast growth factor complexed with biodegradable hydrogels. , 1998, Biomaterials.

[35]  B. V. von Specht,et al.  Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. , 1998, Circulation.

[36]  M. Humphries,et al.  Molecular basis of ligand recognition by integrin alpha 5beta 1. I. Specificity of ligand binding is determined by amino acid sequences in the second and third NH2-terminal repeats of the alpha subunit. , 2000, The Journal of biological chemistry.